London, 04 June 2015: Technavio, the independent tech-focused global research firm, has published a report on the global heparin market 2015-2019, which is expected to post a CAGR of 4.80% during the forecast period of 2014-2019.
The exploitation of novel therapeutic applications of heparin and the emergence of strategic alliances among vendors is expected to propel market growth. Also, an increase in the incidence of acute coronary syndrome and macrovascular disease, leading to thrombosis, may have a positive impact on the market.
“Co-development agreements for different geographical segments enable the penetration of drugs into particular regions,” says Faisal Ghaus, Vice President of Technavio.
“To capture maximum market shares and expand the focus area, vendors are investing more in R&D. For instance, Pfizer and the Ontario Clinical Oncology Group conducted a joint study to identify the survival rates of patients with epithelial ovarian carcinoma when dalteparin is used.”
Key Market Drivers
- Growing Prevalence of Diseases
- Increase in Supply of Crude Heparin
- Reintroduction of Bovine Heparin by FDA
Key Market Trends
- Expected Exploitation of New Therapeutic Use
- Increase in R&D
- Strategic Alliances
- Entry of New Heparin Antidotes
Key Market Vendors
- Aspen
- LEO Pharma A/S
- Pfizer Inc.
- Sanofi-Aventis GmbH
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
